The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
Biocon Foundation has pioneered a mHealth-technology-based (mobile health) oral cancer screening program in India
Medical Tourism will boost India’s economy
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
Granules now have a total of 53 ANDA approvals from USFDA
Asthma patients are more likely to have an asthma attack during winter
He was previously associated with renowned companies such as Granules India Ltd, Dr. Reddy’s Laboratories ltd & Aptar Group
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
Subscribe To Our Newsletter & Stay Updated
